Supernus Pharmaceuticals (SUPN)
(Delayed Data from NSDQ)
$46.13 USD
+1.33 (2.97%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $46.14 +0.01 (0.02%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth D Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SUPN 46.13 +1.33(2.97%)
Will SUPN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SUPN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SUPN
Biogen Gets EU Nod for First Postpartum Depression Drug
Supernus (SUPN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
SUPN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates
Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
Biogen Gears Up to Report Q2 Earnings: Here's What to Expect
Other News for SUPN
Is SUPN likely to continue lower? 20 Day Moving Average Resistance shows up after rising 1.84%
SUPN forms NR7 on September 16
Supernus Pharmaceuticals: Heading In The Right Direction
SUPN Fell Below 20 Day Moving Average on September 15
Top Executive Sells Thousands of Supernus Pharmaceuticals Shares!